Regulatory aspects of specific immunotherapy in Europe
Authors:
- Lisa EnglertLELisa Englert
- Sibylle MaySMSibylle May
- Stefan ViethsSVStefan Vieths
- 1 December 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 10 (6) , 594-602
Abstract
The recent developments in the regulation of allergen products and their impact on specific immunotherapy (SIT) in Europe are summarized, and unmet needs are discussed. New guidance on the quality, the clinical development, and marketing authorization status of allergen products for SIT has been released. The most important documents are Guidelines from the European Medicines Agency, a revision of the European Pharmacopoeia Monograph on Allergens, regulations, and position papers of scientific societies. The increased demands on quality, safety, and efficacy will lead to allergen products being better characterized and with enhanced proof of efficacy and safety. In addition, national activities to regulate the existing broad spectrum of named patient allergen products have been started. At the same time these developments represent a challenge to manufacturers to meet all new requirements. Some problems, for example regarding patient-tailored products containing recombinant allergens remain and may require novel regulatory approaches.Keywords
This publication has 16 references indexed in Scilit:
- Comparison of allergen immunotherapy practice patterns in the United States and EuropeAnnals of Allergy, Asthma & Immunology, 2009
- Standardization of allergen products: 1. Detailed characterization of GMP‐produced recombinant Bet v 1.0101 as biological reference preparationAllergy, 2009
- Detection of allergen composition and in vivo immunogenicity of depigmented allergoids of Betula albaClinical & Experimental Allergy, 2009
- New frontiers in allergen standardization.Clinical & Experimental Allergy, 2009
- The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccinesJournal of Allergy and Clinical Immunology, 2008
- The Principle of Homologous Groups in Regulatory Affairs of Allergen Products – A ProposalInternational Archives of Allergy and Immunology, 2008
- The Regulatory System in Europe with Special Emphasis on Allergen ProductsInternational Archives of Allergy and Immunology, 2008
- Standardization of allergen extracts for immunotherapy: where do we stand?Current Opinion in Allergy and Clinical Immunology, 2006
- FURTHER OBSERVATIONS ON THE TREATMENT OF HAY FEVER BY HYPODERMIC INOCULATIONS OF POLLEN VACCINE.The Lancet, 1911
- PROPHYLACTIC INOCULATION AGAINST HAY FEVERThe Lancet, 1911